Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
Yan Wu, Meihao Wei, Jing Zhang
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 11

Showing 11 citing articles:

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
Fan Zou, Chengyu Zhu, Siyu Lou, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 28
Safety of Janus kinase inhibitors in rheumatoid arthritis: a disproportionality analysis using FAERS database from 2012 to 2022
Bahar Mikaeili, Zuhair Alqahtani, Ana L. Hincapie, et al.
Clinical Rheumatology (2025)
Open Access | Times Cited: 1
From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis
Zhiwei Cui, Zhen Zhai, De Xie, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database
Yongfu Song, Zhuang Wang, Na Wang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
First-in-human study of CPL’116 – a dual JAK/ROCK inhibitor – in healthy subjects
Piotr J. Rudzki, Katarzyna Jarus‐Dziedzic, Dorota Włodarczyk, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases
Qian Liu, Zhiwei Cui, Chao Deng, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database
Yanjing Zhang, Chunhua Zhou, Yan Liu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database
Jiayu Yuan, Hongxia Lu, Xulei Zuo, et al.
Pharmacoepidemiology and Drug Safety (2024) Vol. 33, Iss. 10
Open Access | Times Cited: 1
A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin
Zhongliang Xu, Dan Huang, Q. Liu, et al.
Expert Opinion on Drug Safety (2024), pp. 1-9
Closed Access
A real-world pharmacovigilance study of tafasitamab: data mining of the US food and drug administration adverse event reporting system
Zhongliang Xu, Fangjian Shi, Dan Huang, et al.
Expert Opinion on Drug Safety (2024), pp. 1-11
Closed Access
A Case of Upadacitinib-Associated Ileus Secondary to Psoriasis Induced by Treatment of Atopic Dermatitis with Dupilumab
Xiaoyang Liu, Zhanglei Mu, Lin Cai
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 2855-2858
Open Access
Page 1

Scroll to top